Pioglitazone and bladder cancer risk: a multipopulation pooled, cumulative exposure analysis

Diabetologia

Volumn 58, Issue 3, 2015, Pages 493-504

  Levin, Daniel ^a   Bell, Samira ^b   Sund, Reijo ^c   Hartikainen, Sirpa A ^d   Tuomilehto, Jaakko ^c,e,f,g   Pukkala, Eero ^h,i   Keskimäki, Ilmo ^e,i   Badrick, Ellena ^j   Renehan, Andrew G ^k   Buchan, Iain E ^k   Bowker, Samantha L ^l   Minhas Sandhu, Jasjeet K ^l   Zafari, Zafar ^m   Marra, Carlo ⁿ   Johnson, Jeffrey A ^l   Stricker, Bruno H ^o,p   Uitterlinden, Andrè G ^o   Hofman, Albert ^o   Ruiter, Rikje ^q   de Keyser, Catherine E ^o,p   MacDonald, Thomas M ^b   Wild, Sarah H ^r   McKeigue, Paul M ^r   Colhoun, Helen M ^a,s   more..

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b UNIVERSITY OF DUNDEE   (United Kingdom)

^c UNIVERSITY OF HELSINKI   (Finland)

^d UNIVERSITY OF EASTERN FINLAND   (Finland)

^e NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^f DANUBE UNIVERSITY KREMS   (Austria)

^g KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

^h FINNISH CANCER REGISTRY   (Finland)

ⁱ TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^j UNIVERSITY OF MANCHESTER   (United Kingdom)

^k UNIVERSITY OF MANCHESTER   (United Kingdom)

^l UNIVERSITY OF ALBERTA   (Canada)

^m VANCOUVER COASTAL HEALTH   (Canada)

ⁿ UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^o ERASMUS MEDICAL CENTER   (Netherlands)

^p Inspectorate of Health Care   (Netherlands)

^q GROENE HART HOSPITAL   (Netherlands)

^r UNIVERSITY OF EDINBURGH   (United Kingdom)

^s NHS FIFE   (United Kingdom)

more..

Author keywords

Bladder cancer; Epidemiology; Meta analysis; Pioglitazone; Rosiglitazone; Thiazeolidinedione

Indexed keywords

INSULIN; METFORMIN; PIOGLITAZONE; ROSIGLITAZONE; SULFONYLUREA DERIVATIVE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BLADDER CANCER; BODY MASS; CANADA; CANCER INCIDENCE; CANCER RISK; CLINICAL PRACTICE; COHORT ANALYSIS; DISEASE DURATION; DRUG EXPOSURE; FEMALE; FINLAND; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; PRESCRIPTION; PRIORITY JOURNAL; SMOKING; UNITED KINGDOM; CHEMICALLY INDUCED; DIABETES MELLITUS, TYPE 2; INCIDENCE; MIDDLE AGED; URINARY BLADDER NEOPLASMS;

AGED; BRITISH COLUMBIA; DIABETES MELLITUS, TYPE 2; FEMALE; FINLAND; HUMANS; HYPOGLYCEMIC AGENTS; INCIDENCE; MALE; MIDDLE AGED; SCOTLAND; THIAZOLIDINEDIONES; URINARY BLADDER NEOPLASMS;

EID: 84924662049     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-014-3456-9     Document Type: Article

References (35)

1. Larsson SC, Orsini N, Brismar K, Wolk A (2006) Diabetes mellitus and risk of bladder cancer: a meta-analysis. Diabetologia 49:2819–2823
2. Ferlay J SI, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray, F. Cancer incidence and mortality worldwide: IARC CancerBase No. 11. Available from http://globocan.iarc.fr, accessed 13 Dec 2013
3. Yoshimura R, Matsuyama M, Segawa Y et al (2003) Expression of peroxisome proliferator-activated receptors (PPARs) in human urinary bladder carcinoma and growth inhibition by its agonists. Int J Cancer 104:597–602
4. Nakashiro KI, Hayashi Y, Kita A et al (2001) Role of peroxisome proliferator-activated receptor gamma and its ligands in non-neoplastic and neoplastic human urothelial cells. Am J Pathol 159:591–597
5. Suzuki S, Arnold LL, Pennington KL et al (2010) Effects of pioglitazone, a peroxisome proliferator-activated receptor gamma agonist, on the urine and urothelium of the rat. Toxicol Sci 113:349–357
6. Dormandy JA, Charbonnel B, Eckland DJ et al (2005) Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 366:1279–1289
7. Erdmann E, Dormandy JA, Massi-Benedetti M, Spanheimer R (2011) Pioglitazone and bladder cancer? Authors’ reply. Lancet 378:1544–1545
8. Lewis JD, Ferrara A, Peng T et al (2011) Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study. Diabetes Care 34:916–922
9. Neumann A, Weill A, Ricordeau P, Fagot JP, Alla F, Allemand H (2012) Pioglitazone and risk of bladder cancer among diabetic patients in France: a population-based cohort study. Diabetologia 55:1953–1962
10. Food and Drug Administration (2010) FDA drug safety communication: ongoing safety review of Actos (pioglitazone) and potential increased risk of bladder cancer after two years exposure. Available from www.fda.gov/drugs/drugsafety/ucm226214.htm, accessed 15 Jun 2014
11. European Medicines Agency (2011) European Medicines Agency recommends new contra-indications and warnings for pioglitazone to reduce small increased risk of bladder cancer. Available from www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2011/07/news_detail_001311.jsp&mid=WC0b01ac058004d5c1, accessed 15 Jun 2014
12. Azoulay L, Yin H, Filion KB et al (2012) The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case-control study. BMJ 344:e3645
13. Colmers IN, Bowker SL, Majumdar SR, Johnson JA (2012) Use of thiazolidinediones and the risk of bladder cancer among people with type 2 diabetes: a meta-analysis. CMAJ 184:E675–E683
14. Ferwana M, Firwana B, Hasan R et al (2013) Pioglitazone and risk of bladder cancer: a meta-analysis of controlled studies. Diabet Med 30:1026–1032
15. Fujimoto K, Hamamoto Y, Honjo S et al (2013) Possible link of pioglitazone with bladder cancer in Japanese patients with type 2 diabetes. Diabetes Res Clin Pract 99:e21–e23
16. Hsiao FY, Hsieh PH, Huang WF, Tsai YW, Gau CS (2013) Risk of bladder cancer in diabetic patients treated with rosiglitazone or pioglitazone: a nested case-control study. Drug Saf 36:643–649
17. Kuo HW, Tiao MM, Ho SC, Yang CY (2014) Pioglitazone use and the risk of bladder cancer. Kaohsiung J Med Sci 30:94–97
18. MacKenzie T, Zens MS, Ferrara A, Schned A, Karagas MR (2011) Diabetes and risk of bladder cancer: evidence from a case-control study in New England. Cancer 117:1552–1556
19. Piccinni C, Motola D, Marchesini G, Poluzzi E (2011) Assessing the association of pioglitazone use and bladder cancer through drug adverse event reporting. Diabetes Care 34:1369–1371
20. Song SO, Kim KJ, Lee BW, Kang ES, Cha BS, Lee HC (2012) The risk of bladder cancer in Korean diabetic subjects treated with pioglitazone. Diabetes Metab J 36:371–378
21. Tseng CH (2012) Pioglitazone and bladder cancer: a population-based study of Taiwanese. Diabetes Care 35:278–280
22. Tseng CH (2013) Rosiglitazone is not associated with an increased risk of bladder cancer. Cancer Epidemiol 37:385–389
23. Wei L, MacDonald TM, Mackenzie IS (2013) Pioglitazone and bladder cancer: a propensity score matched cohort study. Br J Clin Pharmacol 75:254–259
24. Zhu Z, Shen Z, Lu Y, Zhong S, Xu C (2012) Increased risk of bladder cancer with pioglitazone therapy in patients with diabetes: a meta-analysis. Diabetes Res Clin Pract 98:159–163
25. Tseng CH (2014) A review on thiazolidinediones and bladder cancer in human studies. J Environ Sci Health Part C Environ Carcinog Ecotoxicol Rev 32:1–45
26. Suissa S, Azoulay L (2012) Metformin and the risk of cancer: time-related biases in observational studies. Diabetes Care 35:2665–2673
27. Colhoun HM, Livingstone SJ, Looker HC et al (2012) Hospitalised hip fracture risk with rosiglitazone and pioglitazone use compared with other glucose-lowering drugs. Diabetologia 55:2929–2937
28. Rodríguez G (2007) Lecture notes on generalized linear models. Available from http://data.princeton.edu/wws509/notes/, accessed 14 Jun 2014
29. Thompson WA Jr (1977) On the treatment of grouped observations in life studies. Biometrics 33:463–470
30. Lewis JD, Habel L, Quesenberry C et al (2014) Proteinuria testing among patients with diabetes mellitus is associated with bladder cancer diagnosis: potential for unmeasured confounding in studies of pioglitazone and bladder cancer. Pharmacoepidemiol Drug Saf 2:636–645
31. Tseng CH (2011) Diabetes and risk of bladder cancer: a study using the National Health Insurance database in Taiwan. Diabetologia 54:2009–2015
32. Cancer Research UK. Bladder cancer risks and causes. Available from www.cancerresearchuk.org/cancer-help/type/bladder-cancer/about/bladder-cancer-risks-and-causes, accessed 15 Jun 2014
33. Turner RM, Kwok CS, Chen-Turner C, Maduakor CA, Singh S, Loke YK (2014) Thiazolidinediones and associated risk of bladder cancer: a systematic review and meta-analysis. Br J Clin Pharmacol 78:258–273
34. Feeley J, Matsuyama K (2014) Takeda, Lilly jury awards $9 billion over Actos risks. Available from www.bloomberg.com/news/2014–04–07/takeda-actos-jury-awards-6-billion-in-punitive-damages.html, accessed 15 Jun 2014
35. Romero V, Peyton C, Gray I, Hemal A, Terlecki R (2014) Pathology of bladder cancer among diabetic patients undergoing radical cystectomy with a history of pioglitazone (Actos) use. BMC Urol 14:10